U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H19N5O6S2
Molecular Weight 453.493
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of CEFCAPENE

SMILES

[H][C@]12SCC(COC(N)=O)=C(N1C(=O)[C@H]2NC(=O)C(=C/CC)\C3=CSC(N)=N3)C(O)=O

InChI

InChIKey=HJJRIJDTIPFROI-NVKITGPLSA-N
InChI=1S/C17H19N5O6S2/c1-2-3-8(9-6-30-16(18)20-9)12(23)21-10-13(24)22-11(15(25)26)7(4-28-17(19)27)5-29-14(10)22/h3,6,10,14H,2,4-5H2,1H3,(H2,18,20)(H2,19,27)(H,21,23)(H,25,26)/b8-3-/t10-,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H19N5O6S2
Molecular Weight 453.493
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/18347113 | https://www.ncbi.nlm.nih.gov/pubmed/26440444

Cefcapene is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcapene binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Giasion

Approved Use

GIASION is indicated for treatment of the following infections caused by susceptible microorganisms: (see section 5.1 pharmacodynamic properties): Pharyngo-acute tonsillitis Acute maxillary sinusitis Acute exacerbation of chronic bronchitis Community acquired pneumonia, mild or moderate Infections uncomplicated skin and skin structures, such as cellulitis, wound infections, abscesses, folliculitis, impetigo and boils.
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Comparison of the efficacies of oral beta-lactams in selection of Haemophilus influenzae transformants with mutated ftsI genes.
2008 May
Patents

Sample Use Guides

Oral antibiotic therapy (CFPN-PI (CEFCAPENE), 300 mg/day) were started, resulting in gradual improvement of the skin lesion to a PPPASI score of 1 and a VAS score of 2.2 after 2 months
Route of Administration: Oral
A spontaneous rifampin-resistant H. influenzae Rd clone, designated RdRIF (19), and two BLNAR isolates (MSC06647 and MSC06663) were used in this study. Cefcapene activity was determined by the broth dilution method. Cefcapene shows potent antimicrobial activity with MIC 0.008mg/ml (for RdRIF), 0.25mg/ml (for MSC06647) and 2 mg/ml (for MSC06663).
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:39:10 GMT 2023
Edited
by admin
on Fri Dec 15 16:39:10 GMT 2023
Record UNII
4D5D3422MW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CEFCAPENE
INN   MI   WHO-DD  
INN  
Official Name English
cefcapene [INN]
Common Name English
Cefcapene [WHO-DD]
Common Name English
CEFCAPENE [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C357
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
WHO-ATC J01DD17
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
WHO-VATC QJ01DD17
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
Code System Code Type Description
MERCK INDEX
m3190
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL582912
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
NCI_THESAURUS
C76160
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
EVMPD
SUB07383MIG
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
DRUG CENTRAL
4159
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
CAS
135889-00-8
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
FDA UNII
4D5D3422MW
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
DRUG BANK
DB13461
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
INN
7006
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID201027544
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
PUBCHEM
6436055
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
SMS_ID
100000081795
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
WIKIPEDIA
CEFCAPENE
Created by admin on Fri Dec 15 16:39:10 GMT 2023 , Edited by admin on Fri Dec 15 16:39:10 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY